If you have been reading about HPLC-UV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-03-15. Numbers and descriptions here follow the published literature rather than marketing material.
Commercial creatine monohydrate is typically manufactured through chemical synthesis, often starting from sarcosine and cyanamide. The resulting material is crystallized, washed, and dried to a specified hydrate content. Finished lots are tested for identity, purity, moisture, and heavy metals before release. Because the compound can cyclize to creatinine under heat or prolonged storage in solution, manufacturers control temperature and humidity during processing. The solid itself is relatively stable when kept dry and sealed, but moisture uptake can cause caking and complicate accurate assay.
Analytical laboratories commonly identify creatine monohydrate by high-performance liquid chromatography with ultraviolet detection, often after dissolving the sample in water or dilute acid. Ion-exchange or reversed-phase columns separate creatine from creatinine and related guanidino compounds. Nitrogen content can be checked by Kjeldahl or combustion methods, while moisture is measured by Karl Fischer titration or loss on drying. These techniques give complementary views: chromatographic purity addresses related substances, whereas moisture and elemental data confirm hydrate stoichiometry. No single test defines quality by itself; a combination is used in specifications.
Storage recommendations generally emphasize a cool, dry place away from direct sunlight and strong oxidizers. Sealed containers limit humidity exchange, which helps prevent clumping and gradual conversion to creatinine. Long-term stability studies usually monitor appearance, moisture, and purity at intervals under defined temperature and humidity conditions. Accelerated tests at elevated temperature can reveal degradation pathways, but they do not perfectly predict room-temperature shelf life. Questions remain about how much creatinine formation is acceptable in different product categories and how packaging choices affect that rate over time.
Manufacturing processes can leave trace amounts of dicyandiamide, creatinine, or residual solvents, depending on the synthetic route and purification steps. Heavy metals, arsenic, and microbial contamination are also monitored for food or pharmaceutical grades. Particle size distribution can affect dissolution behavior and blending uniformity, so it may be specified for certain applications. Analytical results are reported on a dry basis or as-is basis, and the difference matters when comparing certificates of analysis. Open questions remain about how minor impurities influence long-term stability under varied storage conditions.
Stability studies typically examine the effects of temperature, humidity, and light on creatine monohydrate. Sealed containers stored in cool, dry conditions help limit moisture uptake and hydrolysis. Elevated temperature and high relative humidity can accelerate conversion to creatinine, especially in aqueous solutions. In solid dosage forms, excipients and processing steps may also affect stability. Published stability data are not fully consistent across studies because test conditions and analytical methods vary.
Quality control of creatine monohydrate relies on a combination of identity, purity, and moisture tests. High-performance liquid chromatography with ultraviolet detection is widely used to separate creatine from creatinine and other related nitrogenous compounds. Spectroscopic methods such as infrared and nuclear magnetic resonance provide structural confirmation. Because the material is a hydrate, water content is measured separately, often by Karl Fischer titration. These tests together establish whether a lot meets a defined specification.
| Property | Value | Notes |
|---|---|---|
| Common analytical method | HPLC-UV | Separation from creatinine and related compounds. |
| Moisture content | Typically 12% theoretical | Monohydrate stoichiometry corresponds to about 12% water by mass. |
| Typical storage temperature | 15–25 °C | Cool, dry, sealed conditions limit moisture uptake. |
| Degradation marker | Creatinine | Formed by cyclization, especially in solution or with heat. |
| Solubility class | Moderately soluble in water | Solubility rises with temperature and varies with pH. |
Solid creatine monohydrate is generally stable when kept dry and protected from extremes of heat and humidity. In the presence of moisture, it can gradually convert to creatinine, a cyclic dehydration product that has little value for phosphocreatine synthesis. Elevated temperatures and acidic conditions accelerate this conversion in solution. Because the reaction is slow in cool, dry storage, typical shelf lives are measured in years rather than weeks. Packaging that limits moisture and oxygen exposure helps maintain purity.
Recommended storage usually involves a sealed container kept at room temperature, away from direct sunlight and moisture. High humidity can cause caking, which changes flow properties and may complicate accurate weighing. Repeated opening of containers exposes the powder to air and moisture, so smaller aliquots can reduce handling effects. Storage temperature ranges are not absolute requirements; they reflect conditions that slow degradation and preserve consistent physical characteristics. Clean, dry tools help prevent contamination during sampling.
Identity and purity are commonly assessed by high-performance liquid chromatography, often with ultraviolet detection, and by spectroscopic techniques such as infrared or nuclear magnetic resonance. These methods can distinguish creatine from creatinine and detect related impurities. Moisture content may be measured by Karl Fischer titration or loss on drying. Particle size, bulk density, and heavy metal limits are additional quality parameters. Not every product is tested by every method, so specifications depend on the intended use and regulatory framework.
In aqueous solution, creatine monohydrate undergoes a slow conversion to creatinine, a cyclized degradation product. This reaction is pH- and temperature-dependent, and it proceeds faster in warm or alkaline conditions. Because the conversion is gradual, analytical measurements of creatine in solution must account for time and storage history. The equilibrium favors creatinine more strongly at higher temperatures, which is relevant to sample handling in laboratories and to beverage formulations. Refrigeration slows but does not entirely stop this process.
Quality assessment of creatine monohydrate typically uses high-performance liquid chromatography to separate creatine from creatinine and other impurities. Other methods include nuclear magnetic resonance spectroscopy, titration, and infrared spectroscopy for identity confirmation. Purity is often reported as a percentage of the labeled compound on a dry basis, while moisture content is measured separately. Because different analytical methods have different selectivity, comparing purity values across sources requires attention to the method and sample preparation.
In dry solid form, creatine monohydrate is relatively stable when protected from moisture and heat. The crystal lattice includes water, and exposure to high humidity can cause caking or gradual changes in powder flow. Elevated temperatures may accelerate decomposition, particularly if moisture is present. Studies generally report that sealed, dry material retains acceptable purity for extended periods, although exact shelf life depends on packaging and storage conditions. Light exposure is not usually considered a major factor for this compound.
Pyzdek, T, "Quality Engineering Handbook", 2003, ISBN 0-8247-4614-7 De Feo, J. A., "Juran's Quality Handbook", 2016, ISBN 978-1-25964-361-3 ASTM E105 Standard Practice for Probability Sampling of Materials ASTM E122 Standard Practice for Calculating Sample Size to Estimate, With a Specified Tolerable Error, the Average for Characteristic of a Lot or Process ASTM E141 Standard Practice for Acceptance of Evidence Based on the Results of Probability Sampling ASTM E1402 Standard Terminology Relating to Sampling ASTM E1994 Standard Practice for Use of Process Oriented AOQL and LTPD Sampling Plans ASTM E2234 Standard Practice for Sampling a Stream of Product by Attributes Indexedby AQL Sampling procedures for inspection by attributes, ISO 2859-1:1999 Sampling procedures for inspection by attributes, JIS Z 9015-1:2006 Acceptance Sampling Calculators (SQC Online) (A subscription fee is required to use the calculators. The "free" calculations have locked features.)
Glycogenolysis and gluconeogenesis in liver. Glycogenolysis and lactate release in skeletal muscle. Contract sphincters of Gastrointestinal tract. Thickened secretions from salivary glands. Insulin and glucagon secretion from pancreas. Inhibit histamine-release from mast cells. Increase protein content of secretions from lacrimal glands. Receptor also present in cerebellum. Bronchiole dilation (targeted while treating asthma attacks) Involved in brain - immune - communication Short-acting β2 agonists (SABA) bitolterol fenoterol hexoprenaline isoprenaline (INN) or isoproterenol (USAN) levosalbutamol (INN) or levalbuterol (USAN) orciprenaline (INN) or metaproterenol (USAN) pirbuterol procaterol salbutamol (INN) or albuterol (USAN) terbutaline Long-acting β2 agonists (LABA) arformoterol (some consider it to be an ultra-LABA) bambuterol clenbuterol formoterol salmeterol Ultra-long-acting β2 agonists (ultra-LABA) carmoterol indacaterol milveterol (GSK 159797) olodaterol vilanterol (GSK 642444)
The characterization of the caspases allowed the development of caspase inhibitors, which can be used to determine whether a cellular process involves active caspases. Using these inhibitors, it was discovered that cells can die while displaying a morphology similar to apoptosis without caspase activation. Later studies linked this phenomenon to the release of AIF (apoptosis-inducing factor) from the mitochondria and its translocation into the nucleus mediated by its nuclear localization signal (NLS). Inside the mitochondria, AIF is anchored to the inner membrane. In order to be released, the protein is cleaved by a calcium-dependent calpain protease. Anoikis Apaf-1 Apo2.7 Apoptotic DNA fragmentation Atromentin induces apoptosis in human leukemia U937 cells. Autolysis Autophagy Cisplatin Cytotoxicity Entosis Ferroptosis Homeostasis Immunology Necrobiosis Necrosis Necrotaxis Nemosis Mitotic catastrophe p53 Paraptosis Pseudoapoptosis PI3K/AKT/mTOR pathway Ruptosis
The binding of S-arrestin to rhodopsin is specific and involves changes that occur in rhodopsin after activation. Important serine (Ser) and threonine (Thr) residues in rhodopsin's tail, particularly Thr-340 and Ser-343, are phosphorylated by enzymes called GRKs. These phosphorylated residues strongly attract S-arrestin, helping it bind tightly and effectively shut down rhodopsin's signaling. Additionally, studies of the protein structure have shown that during activation, rhodopsin's transmembrane helix 7 (TM7) and helix 8 change shape. These changes expose a binding site that interacts with a specific part of arrestin called the "finger loop." This interaction, clearly seen in the crystal structure (PDB ID: 4ZWJ), shows how arrestin fits precisely onto activated and phosphorylated rhodopsin, efficiently stopping the visual signal. Arrestin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
Biomaterials are used in: Joint replacements Bone plates Intraocular lenses (IOLs) for eye surgery Bone cement Artificial ligaments and tendons Dental implants for tooth fixation Blood vessel prostheses Heart valves Skin repair devices (artificial tissue) Cochlear replacements Contact lenses Breast implants Drug delivery mechanisms Sustainable materials Vascular grafts Stents Nerve conduits Surgical sutures, clips, and staples for wound closure Pins and screws for fracture stabilisation Surgical mesh Biomaterials must be compatible with the body, and there are often issues of biocompatibility, which must be resolved before a product can be placed on the market and used in a clinical setting. Because of this, biomaterials are usually subjected to the same requirements as those undergone by new drug therapies. All manufacturing companies are also required to ensure traceability of all of their products, so that if a defective product is discovered, others in the same batch may be traced.
Membrane interaction of alpha-synuclein modulates or affects its rate of aggregation. The membrane-mediated modulation of aggregation is very similar to that observed for other amyloid proteins such as IAPP and abeta. Aggregated states of alpha-synuclein permeate the membrane of lipid vesicles. They are formed upon interaction with peroxidation-prone polyunsaturated fatty acids (PUFA) but not with monounsaturated fatty acids and the binding of lipid autoxidation-promoting transition metals such as iron or copper provokes oligomerization of alpha-synuclein. The aggregated alpha-synuclein has a specific activity for peroxidized lipids and induces lipid autoxidation in PUFA-rich membranes of both neurons and astrocytes, decreasing resistance to apoptosis. Lipid autoxidation is inhibited if the cells are pre-incubated with isotope-reinforced PUFAs (D-PUFA).
Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. The US Food and Drug Administration considers it to be a first-in-class medication.
Sources: en.wikipedia.org
Laboratories typically combine chromatographic separation with moisture and elemental analysis. High-performance liquid chromatography can quantify creatine and related substances such as creatinine. Moisture methods confirm the hydrate form and help detect excess water.
The dry crystalline solid is relatively stable when protected from moisture and heat. In solution, it can convert to creatinine over time, especially at higher temperatures. Storage conditions and product form influence the rate of change.
Moisture uptake can cause particles to stick together, particularly in humid conditions or after opening a container. Clumping does not necessarily mean the creatine has degraded. It can make accurate measuring more difficult, so dry storage and sealed packaging are used.
Purity is commonly assessed by HPLC, which separates creatine from related compounds such as creatinine. Water content is measured separately by Karl Fischer titration. Together these results help calculate the actual creatine content in a sample.